Mustang bio announces favorable efficacy and safety data from complete waldenstrom macroglobulinemia cohort of phase 1/2 clinical trial of mb-106, cd20-targeted autologous car-t therapy

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months
CAR Ratings Summary
CAR Quant Ranking